203 related articles for article (PubMed ID: 27264436)
1. Ginkgo biloba and vitamin E ameliorate haloperidol-induced vacuous chewingmovement and brain-derived neurotrophic factor expression in a rat tardive dyskinesia model.
Shi J; Tan YL; Wang ZR; An HM; Li J; Wang YC; Lv MH; Yan SX; Wu JQ; Soares JC; Yang FD; Zhang XY
Pharmacol Biochem Behav; 2016 Sep; 148():53-8. PubMed ID: 27264436
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of EGb761 and vitamin E on haloperidol-induced vacuous chewing movements in rats: Possible involvement of S100B mechanisms.
An HM; Tan YL; Shi J; Wang ZR; Li J; Wang YC; Lv MH; Zhou DF; Soares JC; Kosten TR; Yang FD; Zhang XY
Behav Brain Res; 2016 Jan; 297():124-30. PubMed ID: 26455874
[TBL] [Abstract][Full Text] [Related]
3. Extract of Ginkgo biloba is equivalent to vitamin E in attenuating and preventing vacuous chewing movements in a rat model of tardive dyskinesia.
An HM; Tan YL; Shi J; Wang ZR; Li J; Wang YC; Kosten TR; Zhou DF; Yang FD; Zhang XY
Behav Pharmacol; 2013 Oct; 24(7):610-6. PubMed ID: 23994817
[TBL] [Abstract][Full Text] [Related]
4. Ginkgo biloba leaf extract and alpha-tocopherol attenuate haloperidol-induced orofacial dyskinesia in rats: Possible implication of antiapoptotic mechanisms by preventing Bcl-2 decrease and Bax elevation.
An HM; Tan YL; Shi J; Wang Z; Lv MH; Soares JC; Zhou D; Yang F; Zhang XY
Phytomedicine; 2016 Dec; 23(13):1653-1660. PubMed ID: 27823630
[TBL] [Abstract][Full Text] [Related]
5. Lipoic acid and haloperidol-induced vacuous chewing movements: Implications for prophylactic antioxidant use in tardive dyskinesia.
Lister J; Andreazza AC; Navaid B; Wilson VS; Teo C; Nesarajah Y; Wilson AA; Nobrega JN; Fletcher PJ; Remington G
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Jan; 72():23-29. PubMed ID: 27565433
[TBL] [Abstract][Full Text] [Related]
6. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
[TBL] [Abstract][Full Text] [Related]
7. Harpagophytum Procumbens Ethyl Acetate Fraction Reduces Fluphenazine-Induced Vacuous Chewing Movements and Oxidative Stress in Rat Brain.
Schaffer LF; de Freitas CM; Chiapinotto Ceretta AP; Peroza LR; de Moraes Reis E; Krum BN; Busanello A; Boligon AA; Sudati JH; Fachinetto R; Wagner C
Neurochem Res; 2016 May; 41(5):1170-84. PubMed ID: 26732278
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol.
Egan MF; Hurd Y; Ferguson J; Bachus SE; Hamid EH; Hyde TM
Psychopharmacology (Berl); 1996 Oct; 127(4):337-45. PubMed ID: 8923569
[TBL] [Abstract][Full Text] [Related]
9. Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.
Bordia T; Zhang D; Perez XA; Quik M
Exp Neurol; 2016 Dec; 286():32-39. PubMed ID: 27658674
[TBL] [Abstract][Full Text] [Related]
10. Protective role of endocannabinoid signaling in an animal model of haloperidol-induced tardive dyskinesia.
Röpke J; Ferreira-Vieira TH; Iglesias LP; Asth L; Ribeiro FM; Moreira FA
Pharmacol Biochem Behav; 2021 Jul; 206():173193. PubMed ID: 33933537
[TBL] [Abstract][Full Text] [Related]
11. Central administration of the neurotensin receptor antagonist SR48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia.
McCormick SE; Stoessl AJ
Neuroscience; 2003; 119(2):547-55. PubMed ID: 12770567
[TBL] [Abstract][Full Text] [Related]
12. The effects of sigma-1 agonist fluvoxamine on experimental induced tardive dyskinesia model in rats.
Uslu ET; Mengi M; Beyazyüz E; Çelikkol A; Albayrak Y
Prog Neuropsychopharmacol Biol Psychiatry; 2023 Aug; 126():110787. PubMed ID: 37196751
[TBL] [Abstract][Full Text] [Related]
13. Oral Dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid.
Andreassen OA; Ferrante RJ; Beal MF; Jørgensen HA
Neuroscience; 1998 Dec; 87(3):639-48. PubMed ID: 9758230
[TBL] [Abstract][Full Text] [Related]
14. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains.
Tamminga CA; Dale JM; Goodman L; Kaneda H; Kaneda N
Psychopharmacology (Berl); 1990; 102(4):474-8. PubMed ID: 1982902
[TBL] [Abstract][Full Text] [Related]
15. Antioxidant effects of rice bran oil mitigate repeated haloperidol-induced tardive dyskinesia in male rats.
Samad N; Haleem DJ
Metab Brain Dis; 2017 Aug; 32(4):1099-1107. PubMed ID: 28374238
[TBL] [Abstract][Full Text] [Related]
16. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba.
Zhang XY; Zhang WF; Zhou DF; Chen DC; Xiu MH; Wu HR; Haile CN; Kosten TA; Kosten TR
Biol Psychiatry; 2012 Oct; 72(8):700-6. PubMed ID: 22695185
[TBL] [Abstract][Full Text] [Related]
17. Co-treatment with imipramine averted haloperidol-instigated tardive dyskinesia: Association with serotonin in brain regions.
Samad N; Yasmin F; Haleem DJ
Pak J Pharm Sci; 2016 Nov; 29(6 Suppl):2273-2279. PubMed ID: 28167465
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors.
Sonego AB; Prado DS; Vale GT; Sepulveda-Diaz JE; Cunha TM; Tirapelli CR; Del Bel EA; Raisman-Vozari R; Guimarães FS
Brain Behav Immun; 2018 Nov; 74():241-251. PubMed ID: 30217539
[TBL] [Abstract][Full Text] [Related]
19. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats.
Turrone P; Remington G; Kapur S; Nobrega JN
Psychopharmacology (Berl); 2003 Jan; 165(2):166-71. PubMed ID: 12417967
[TBL] [Abstract][Full Text] [Related]
20. Early gene mapping after deep brain stimulation in a rat model of tardive dyskinesia: comparison with transient local inactivation.
Creed MC; Hamani C; Nobrega JN
Eur Neuropsychopharmacol; 2012 Jul; 22(7):506-17. PubMed ID: 22153973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
